AI Article Synopsis
- The study addresses the issue of urine drug screens mistakenly identifying CBD users as marijuana users due to trace amounts of THC in some CBD products.
- A new assay was developed to differentiate between marijuana use and CBD use contaminated with THC by measuring specific urinary metabolites.
- Results showed that a significant portion of samples from CBD users had higher levels of CBD metabolites compared to THC metabolites, supporting the effectiveness of the assay in correctly classifying users.
Article Abstract
Context: Detecting marijuana use is a component of most urine drug screens targeting a single Δ-tetrahydrocannabinol metabolite. Recently, the non-intoxicating cannabinoid, cannabidiol (CBD), has gained popular acceptance for a myriad of reasons. Commercially available CBD products sold without purity regulations have become ubiquitous. Many products contain trace tetrahydrocannabinol. Long-term or high dose use of CBD products can result in tetrahydrocannabinol exposures, potentially producing a positive marijuana drug test. These results are not false positives since marijuana biomarkers are present, but inaccurately identify donors as marijuana users. Addressing this conundrum, we developed an assay discriminating marijuana use from the use of CBD contaminated with tetrahydrocannabinol.
Methods: Following the synthesis of a primary CBD metabolite, a LC-MS/MS assay was developed measuring the urinary metabolites tetrahydrocannabinol, 11-nor-carboxy-Δ-tetrahydrocannabinol, CBD, and 7-carboxy-cannabidiol. The assay was utilized on 425 patients claiming CBD use, and sixteen samples from trusted users of commercial CBD products.
Results And Discussion: Clear data clusters enabled metabolic cut-points assignments. Forty-three percent of samples contained CBD metabolites in ten-fold excess to tetrahydrocannabinol metabolites which was then used as a set point to classify donors as CBD users. An excess of tetrahydrocannabinol metabolites classify donors as marijuana users. Additionally, urine samples were procured from donors personally known to use commercial CBD , yet abstain from tetrahydrocannabinol. Results from trusted users substantiated the use of the resulting metabolic ratios despite 11-carboxy-tetrahydrocannabinol measured in 75% of these samples.
Conclusion: A method has been developed and utilized to distinguish marijuana use from tetrahydrocannabinol exposure from contaminated CBD use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15563650.2020.1827148 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes.
Clin Transl Sci
January 2025
Department of Chemistry, York College, City University of New York, New York, USA.
The two most extensively studied cannabinoids, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), are used for myriad conditions. THC is predominantly eliminated via the cytochromes P450 (CYPs), whereas CBD is eliminated through both CYPs and UDP-glucuronosyltransferases (UGTs). The fractional contributions of these enzymes to cannabinoid metabolism have shown conflicting results among studies.
View Article and Find Full Text PDFOxidized phospholipid and transcriptomic signatures of THC-related vaping associated lung injury.
Sci Rep
December 2024
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
E-cigarette/vaping-associated lung injury (EVALI) is strongly associated with vitamin E acetate and often occurs with concomitant tetrahydrocannabinol (THC) use. To uncover pathways associated with EVALI, we examined cytokines, transcriptomic signatures, and lipidomic profiles in bronchoalveolar lavage fluid (BALF) from THC-EVALI patients. At a single center, we prospectively enrolled mechanically ventilated patients with EVALI from THC-containing products (N = 4) and patients with non-vaping acute lung injury and airway controls (N = 5).
View Article and Find Full Text PDFCurrent and Potential Use of Biologically Active Compounds Derived from L. in the Treatment of Selected Diseases.
Int J Mol Sci
November 2024
Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska Street141/143, 90-236 Lodz, Poland.
L. contains numerous compounds with antioxidant and anti-inflammatory properties, including the flavonoids and the cannabinoids, particularly Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids have an effect on the endocannabinoid system (ECS), a cellular communication network, and are, hence, widely studied for medical applications.
View Article and Find Full Text PDFQuantification of ∆9-tetrahydrocannabinol (THC), 11-OH-THC, THC-COOH, hexahydrocannabinol and cannabidiol in human plasma and blood by liquid chromatography-tandem mass spectrometry.
J Anal Toxicol
December 2024
Institute of Legal Medicine, Medical University of Innsbruck, Muellerstrasse 44, 6020 Innsbruck, Austria.
Ongoing legalization of cannabis for recreational use contributes to increasing numbers not only of incidents of driving under the influence, but within all forensic fields. In addition, newly emerging cannabinoids such as hexahydrocannabinol (HHC) and the increasing use of cannabidiol (CBD) products have to be addressed. The aims of this study were first to extend laboratory analysis capacity for the "established" cannabinoid ∆9-tetrahydrocannabinol (THC) and its metabolites 11-OH-THC and THC-COOH in human plasma/blood, and second to develop analytical procedures concerning HHC and CBD.
View Article and Find Full Text PDFQuantitative analysis of cannabinoids and metabolites in oral fluid by volumetric absorptive microsampling combined with UHPLC-HRMS.
Anal Bioanal Chem
January 2025
Laboratoire de Toxicologie, Fédération de Toxicologie, Hôpital Lariboisière AP-HP, 2 Rue Ambroise Paré, 75010, Paris, France.
Article Synopsis
- The increasing legalization of cannabis worldwide has led to a growing need for methods to accurately identify and quantify cannabis consumption, especially through non-invasive means.
- Oral fluid, as an alternative to traditional blood and urine tests, offers advantages such as easier self-sampling and reduced risk of tampering, although it typically requires larger volumes to test effectively.
- The study presents a new method that allows for the quantification of seven cannabinoids from just 20 µL of oral fluid using a specialized sampling device and advanced chemical techniques, achieving precise detection limits suitable for legal and clinical contexts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!